checkmate142: checkpoint combination therapy in first-line colorectal cancer
Published 5 years ago • 63 plays • Length 4:31Download video MP4
Download video MP3
Similar videos
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
3:44
keynote-177 & checkmate 142: checkpoint blockade in msi-h/dmmr crc
-
5:30
expert report on immune checkpoint inhibitors for dmmr colorectal cancer
-
6:31
what are checkpoint inhibitors?
-
1:34
checkmate-142: updated data from msi high metastatic colon cancer patients
-
4:00
earlier use of checkpoint inhibitors
-
13:30
checkpoint inhibitor combination therapy for first-line advanced nsclc
-
27:43
targeting the immune system with checkpoint inhibitors
-
2:03
promising checkmate-142 data for second-line ipilimumab plus nivolumab in mcrc
-
2:37
moving forward with results from checkmate-142 in msi-h mcrc
-
1:03
dr. nelson on the checkmate-142 trial in msi-h/dmmr mcrc
-
4:38
emerging checkpoint inhibitors for hnscc
-
1:52
what are checkpoint inhibitors
-
1:14
current and future trends in immunotherapy for msi-h colorectal cancer
-
3:30
dosing regiment in the combination of ipilimumab and nivolumab in stage iii melanoma
-
6:03
two options for checkpoint inhibition in hcc
-
5:44
clinical trials of immune checkpoint inhibitors as first line therapy for advanced nsclc
-
1:51
esmo 2018 highlights in metastatic colorectal cancer checkmate 142
-
5:26
checkpoint inhibitor therapy for treating melanoma